Acadia Pharmaceuticals says USPTO allows trofinetide dosing patent application, extending U.S. protection to March 2041

By Public Technologies
  • ACADIA Pharmaceuticals received a USPTO Notice of Allowance for a U.S. patent covering weight-banded dosing of trofinetide for Rett syndrome.
  • Expected patent term, including six months of pediatric exclusivity, runs through March 28, 2041, extending protection by nearly five years.
  • Trofinetide also has a U.S. method-of-use patent for Rett syndrome that expires in July 2036.
  • Trofinetide is marketed in the U.S. as DAYBUE and DAYBUE STIX for adults and pediatric patients ages 2 and older.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260928764044) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.